GI Dynamics Completes Initial Closing of a $10 Million Series A Preferred Stock Financing from Crystal Amber

by David | Sep 10, 2020 | Press Releases

BOSTON — September 10, 2020 — GI Dynamics® Inc. (‘GI Dynamics” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the initial closing of its private placement offering of...

Further Delisting Update

by David | Jul 15, 2020 | Press Releases

BOSTON and SYDNEY — 15 July 2020 — GI Dynamics® Inc. (ASX:GID) (the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, provides the following update regarding the removal of the Company from the Official...

Conversion of June 2017 Convertible Note

by David | Jul 15, 2020 | Press Releases

BOSTON and SYDNEY — 15 July 2020 — GI Dynamics® Inc. (ASX:GID) (the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, advises that it has received a notice of conversion from Crystal Amber Fund Limited...

Further Extension of Maturity Date of June 2017 Note and Financing Update

by David | Jul 1, 2020 | Press Releases

BOSTON and SYDNEY — 1 July 2020 — GI Dynamics® Inc. (ASX:GID) (”the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, provides the following update regarding the extension of the maturity date of the...

Stockholders Approve Delisting from the Official List

by David | Jun 22, 2020 | Press Releases

BOSTON and SYDNEY — 22 June 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announces that it held its Special Meeting of Stockholders on 21 June 2020...

Placement of $750,000 Unsecured Convertible Promissory Note & Update on Potential Financing and Special Meeting

by David | Jun 19, 2020 | Press Releases

BOSTON and SYDNEY — 19 June 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has issued a US$750,000 Unsecured...

Further Extension of Maturity Date of June 2017 Note & Fundraising Update

by David | Jun 16, 2020 | Press Releases

BOSTON and SYDNEY — 17 June 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, provides the following update regarding the extension of the maturity date...

Further Postponement of Special Meeting of Stockholders

by David | Jun 15, 2020 | Press Releases

BOSTON and SYDNEY — 15 June 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announces a further postponement of the Special Meeting of Stockholders...

Postponement of Special Meeting of Stockholders

by David | Jun 5, 2020 | Press Releases

BOSTON and SYDNEY — 5 June 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announces the postponement of the Special Meeting of Stockholders that was...

Update: Proposed Delisting from the Official List of ASX – Formal Consent of ASX to Delist – Filing of Final Definitive Proxy Statement and Notice of Special Meeting

by David | May 27, 2020 | Press Releases

BOSTON and SYDNEY — 27 May 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, confirms that further to its announcement of 11 May 2020, the Company has...